Voices
Arndt Vogel: Lenvatinib Plus Pembrolizumab Shows Modest Activity in Advanced GI Cancers
Arndt Vogel/aasld.org

Arndt Vogel: Lenvatinib Plus Pembrolizumab Shows Modest Activity in Advanced GI Cancers

Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on X:

“Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Phs II LEAP-005 Study
BTC cohort:

  • ORR 17%
  • mPFS 4.1mo
  • mOS 7.9 mo

Only modest activity in all comers.”

Title: Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study

Authors: Mariano Ponz-Sarvisé, Sun Rha, Carlos Gomez-Roca, Laura Morán, Sanjeev Gill, Giampaolo Tortora, Ravit Geva, Esma Saada-Bouzid, Armando Santoro, Tae Kim, Daniel Heudobler, Corina Dutcus, Chinyere Okpara, Razi Ghori, Yiwei Zhang, Amir Vajdi, E. J.  Dettman, Fan Jin, Roman Groisberg, Ronnie Shapira-Frommer

Read here.

Arndt Vogel

Other articles featuring Arndt Vogel on OncoDaily.

Amir Vajdi Armando Santoro Arndt Vogel cancer Carlos Gomez-Roca Chinyere E. Okpara Corina E. Dutcus Daniel Heudobler E. J. Dettman Esma Saada-Bouzid Fan Jin Giampaolo Tortora Laura Ortega Morán Lenvatinib Mariano Ponz-Sarvise OncoDaily Oncology pembrolizumab Ravit Geva Razi Ghori Roman Groisberg Ronnie Shapira-Frommer Sanjeev Gill Sun Young Rha Tae Won Kim Yiwei Zhang